Cemiplimab: Difference between revisions
Redirected page to Cemiplimab-rwlc Tag: New redirect |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Cemiplimab''' is a [[monoclonal antibody]] used in the treatment of certain types of [[cancer]]. It is marketed under the brand name '''Libtayo'''. Cemiplimab is specifically designed to target the [[programmed cell death protein 1]] (PD-1) receptor, a protein found on the surface of [[T cells]], which are a type of [[white blood cell]] involved in the immune response. | |||
==Mechanism of Action== | |||
Cemiplimab works by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction normally acts as a "brake" on the immune system, preventing T cells from attacking the body's own tissues. However, many [[tumors]] exploit this pathway to evade immune detection. By blocking PD-1, cemiplimab releases this brake, allowing T cells to recognize and destroy cancer cells more effectively. | |||
==Clinical Use== | |||
Cemiplimab is approved for the treatment of [[cutaneous squamous cell carcinoma]] (CSCC), a common form of [[skin cancer]]. It is indicated for patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or radiation. The drug is administered via [[intravenous]] infusion, typically every three weeks. | |||
==Development and Approval== | |||
Cemiplimab was developed by [[Regeneron Pharmaceuticals]] and [[Sanofi]]. It received [[FDA]] approval in 2018 for the treatment of advanced CSCC. The approval was based on clinical trials demonstrating significant tumor shrinkage in a substantial proportion of patients. | |||
==Side Effects== | |||
Common side effects of cemiplimab include fatigue, rash, and diarrhea. More serious immune-mediated side effects can occur, such as pneumonitis, hepatitis, and endocrinopathies. Patients receiving cemiplimab require monitoring for these adverse effects, and treatment may need to be adjusted or discontinued if severe reactions occur. | |||
==Research and Future Directions== | |||
Ongoing research is exploring the use of cemiplimab in other types of cancer, including [[non-small cell lung cancer]] (NSCLC) and [[basal cell carcinoma]] (BCC). Combination therapies with other [[immunotherapies]] or [[chemotherapy]] agents are also under investigation to enhance its efficacy. | |||
==Related Pages== | |||
* [[Monoclonal antibody therapy]] | |||
* [[Programmed cell death protein 1]] | |||
* [[Cutaneous squamous cell carcinoma]] | |||
* [[Regeneron Pharmaceuticals]] | |||
* [[Sanofi]] | |||
[[Category:Monoclonal antibodies]] | |||
[[Category:Antineoplastic and immunomodulating agents]] | |||
[[Category:Immunotherapy]] | |||
Latest revision as of 08:59, 14 March 2025
Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. It is marketed under the brand name Libtayo. Cemiplimab is specifically designed to target the programmed cell death protein 1 (PD-1) receptor, a protein found on the surface of T cells, which are a type of white blood cell involved in the immune response.
Mechanism of Action[edit]
Cemiplimab works by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction normally acts as a "brake" on the immune system, preventing T cells from attacking the body's own tissues. However, many tumors exploit this pathway to evade immune detection. By blocking PD-1, cemiplimab releases this brake, allowing T cells to recognize and destroy cancer cells more effectively.
Clinical Use[edit]
Cemiplimab is approved for the treatment of cutaneous squamous cell carcinoma (CSCC), a common form of skin cancer. It is indicated for patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or radiation. The drug is administered via intravenous infusion, typically every three weeks.
Development and Approval[edit]
Cemiplimab was developed by Regeneron Pharmaceuticals and Sanofi. It received FDA approval in 2018 for the treatment of advanced CSCC. The approval was based on clinical trials demonstrating significant tumor shrinkage in a substantial proportion of patients.
Side Effects[edit]
Common side effects of cemiplimab include fatigue, rash, and diarrhea. More serious immune-mediated side effects can occur, such as pneumonitis, hepatitis, and endocrinopathies. Patients receiving cemiplimab require monitoring for these adverse effects, and treatment may need to be adjusted or discontinued if severe reactions occur.
Research and Future Directions[edit]
Ongoing research is exploring the use of cemiplimab in other types of cancer, including non-small cell lung cancer (NSCLC) and basal cell carcinoma (BCC). Combination therapies with other immunotherapies or chemotherapy agents are also under investigation to enhance its efficacy.
